Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Loss of TRPV4 reduces pancreatic cancer growth and metastasis
Joelle M.-J. Romac, Sandip M. Swain, Nidula Mullappilly, Bandana Bindhani, Rodger A. Liddle
Joelle M.-J. Romac, Sandip M. Swain, Nidula Mullappilly, Bandana Bindhani, Rodger A. Liddle
View: Text | PDF
Research Article Gastroenterology Oncology

Loss of TRPV4 reduces pancreatic cancer growth and metastasis

  • Text
  • PDF
Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a rapidly metastasizing cancer characterized by a dense desmoplastic stroma composed of extracellular matrix (ECM) proteins, which complicates treatment. Upon stimulation, pancreatic stellate cells (PSCs) differentiated into cancer-associated fibroblasts (CAFs) that are the source of ECM and cytokines in PDAC. We previously reported that mechanical stress activates PSCs and induces fibrosis through mechanical ion channel PIEZO1-mediated TRPV4 channel activation, but its role in PDAC remains unclear. Here we report that pathological activation of PIEZO1 differentiated human PSCs into an inflammatory CAF phenotype that expresses chemoresistance and cancer stemness markers CD10 and GPR77. In an orthotopic PDAC model, TRPV4-KO mice exhibited a significant reduction in tumor size, circulating inflammatory cytokines, tissue inhibitor of metalloproteinases-1 (TIMP1), and premetastatic niche markers, serum amyloid A (SAA) proteins. A similar trend was observed in mice lacking functional PIEZO1 in PSCs. The livers of TRPV4-KO mice exhibited fewer cancer cell microlesions, lacked macrotumors, produced lower levels of inflammatory protein S100A8, and developed fewer inflammatory cell clusters. In orthotopic and genetically engineered models of PDAC, these mice also had improved survival, suggesting that blocking TRPV4 channels may be a promising therapeutic target for PDAC.

Authors

Joelle M.-J. Romac, Sandip M. Swain, Nidula Mullappilly, Bandana Bindhani, Rodger A. Liddle

×

Figure 9

TRPV4 loss reduces metastases and increases survival in a GEMM model of PDAC and correlates with increased survival in human pancreatic ductal adenocarcinoma.

Options: View larger image (or click on image) Download as PowerPoint
TRPV4 loss reduces metastases and increases survival in a GEMM model of ...
(A) Survival curve of KPC versus KPC;TRPV4-KO mice. Mice either died with weight loss (left graph) or without weight loss (right graph). Log-rank values are indicated on the graph. (B) Distribution of animals in each category (loss of weight or absence of weight loss). (C) Representative images of liver tissues from KPC mice; upper panel: immunostaining with CK19 antibody; lower panel: IHC with Ki67. Sequential slides were used for staining. Scale bar: 50 μm. (D) Representative images of liver tissues from KPC;TRPV4-KO mice; upper panel: immunostaining with CK19 antibody; lower panel: IHC with Ki67. Sequential slides were used for the staining. Age (days) of each mouse at time of death is listed. Arrows indicate the presence of microlesions. Scale bar: 100 μm. (E) Quantitative analysis of tumor microlesions in liver tissues from KPC or KPC;TRPV4-KO mice. (F) Human pancreatic adenocarcinoma. Left panel: overall survival curves for patients with high TRPV4 expression (upper fifteenth percentile) versus patients with low TRPV4 expression (lowest fifteenth percentile). Right panel: overall survival curves for patients with high PIEZO1 expression (upper fifteenth percentile) versus patients with low PIEZO1 expression (lowest fifteenth percentile). Comparison of survival curves was performed using the Log-Rank (Mantel-Cox) test. Statistical analysis was performed using Student’s t test. Results were expressed as mean ± SEM; **P ≤ 0.01.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts